Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets (Unaudited)

v3.10.0.1
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents [note 6] $ 11,755 $ 5,284
Restricted cash [note 6 and note 9]   222
Short-term investments [note 6] 1,390  
Amounts receivable 25 9
Prepaid expenses 349 393
Total current assets 13,519 5,908
Restricted cash [note 6] 50 50
Property and equipment, net 32 59
Other assets 141 309
License agreement [note 2, 4 and 5] 2,365 2,532
Goodwill [note 2 and 5] 1,034 1,034
Total assets 17,141 9,892
Current liabilities:    
Accounts payable 458 213
Accrued liabilities other 755 438
Accrued clinical liabilities 667 877
Accrued compensation 1,071 458
Current portion of long-term obligations [note 9] 11 27
Total current liabilities 2,962 2,013
Long-term obligations, less current portion [note 9] 15  
Total liabilities 2,977 2,013
Commitments and contingencies [note 9]
Stockholders' equity:    
Series A convertible preferred stock, $0.001 par value, 5,000,000 shares authorized, 652 issued and outstanding at September 30, 2018 and zero issued and outstanding at December 31, 2017.
Common stock, $0.001 par value, 150,000,000 shares authorized, 4,901,095 and 1,195,675 issued at September 30, 2018 and December 31, 2017, respectively, and 4,901,095 and 1,194,793 outstanding at September 30, 2018 and December 31, 2017, respectively. 16 12
Additional paid-in capital 35,887 20,556
Accumulated deficit (21,744) (12,694)
Accumulated other comprehensive income 5 5
Total stockholders' equity 14,164 7,879
Total liabilities and stockholders' equity $ 17,141 $ 9,892